AR and prostate cancer: According to the literature, TFF3 acts as an oncogene because it regulates other genes (FOXA1, HER2, and AR) involved in EMT, thus promoting invasiveness, survival, and increased proliferation in multiple carcinomas such as gastric cancer, mammary carcinoma, and prostate cancer (Yuan et al., 2017).